Skip to main content
14/08/2019 - 10:50

CSL drug sales lift FY profit to $US1.92bn

14/08/2019 - 10:50

Bookmark

Save articles for future reference.

CSL's full-year profit has risen 11 per cent to $US1.92 billion ($A2.82 billion), driven by disease diagnosis and global demand for its immunoglobulin portfolio.

X

To read our articles you will need to either login or subscribe.